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The primary immunodeficiency diseases (PIDs) 
are inherited, non-communicable diseases that 
cause immunological dysfunction. They primarily 
manifest with a wide range of infections. The pattern, 
frequency and severity of infection depend on the 
underlying immunological defect (Table 1), and geographical and social 
determinants. For example, in high tuberculosis (TB) prevalence settings 
chronic granulomatous disease (CGD) may manifest with recurrent TB.
In well-resourced countries, estimates of the prevalence of PIDs vary 
widely from 5.38/100  000 in France to 86.3/100  000 in the USA.[1,2] 
There is very little reporting of PIDs from Africa, including South Africa 
(SA). In the latest Jeffrey Modell Foundation (JMF) global survey, 1 463 
patients with PIDs out of a global total of 77 193 were from Africa.[3] This 
low reporting prevalence of 1.9% contrasts with Africa’s contribution of 
approximately 15% to the global population. Recent speculation suggests 
that as many as 902  000 PID cases should be reported from Africa.[1] 
In SA, based on a mid-2013 population estimate of 52.98 million and 
assuming that the prevalence of PIDs is similar to that in well-resourced 
settings, the total number of people with PIDs should range between 
2 850 and 45 723. However, fewer than 500 PID cases have been reported 
in SA.[4,5]
The almost 300 patients in the SA National PID Registry reflect 
deficiencies similar to those in European and US data, with the 
majority due to antibody deficiencies. Respiratory infections are the 
most common presenting symptom and a positive family history 
is recorded in 30%. Paediatricians outside of tertiary care centres 
contribute a significant third of registry entries. Of special concern 
is the under-reporting of PIDs from disadvantaged communities. 
As infections are common in childhood, a high level of awareness is 
needed to investigate those that may be caused by an immune deficit.
Classification of PIDs
Between five and 15 new, fully characterised PIDs are reported 
annually. Our understanding of the physiology of the immune 
system has been substantially enhanced by these discoveries, and 
consequently the international classification of PIDs has been 
updated. It now includes nearly 250 different PIDs spanning nine 
categories, including a new category, phenocopies of PIDs, which 
contains conditions caused by somatic mutations and autoantibody-
mediated PIDs (Table 2).[6] Given the complexity of the human 
immune system, the rate at which new PIDs are being discovered will 
most likely continue for the foreseeable future, necessitating further 
revision to the international classification.
Investigation
The medical history, clinical presentation and causative organism 
guide the laboratory investigation of PIDs.
Red flag signs in the medical history include severe, persistent, 
unusual and recurrent (SPUR) infections  and, very importantly, a 
history of previous infant death due to infections or a known family 
history of PID. The frequency of infection commonly indicates 
the need for further investigations. Six or more upper respiratory 
infections per year are acceptable in the average toddler.[7] Increased 
frequency is seen with overcrowding and poor sanitation. Aggravating 
factors for recurrent infections such as allergy or daycare have to be 
evaluated. Secondary immunodeficiencies such as HIV infection 
are far more common and have to be excluded initially. Repeated 
infections at the same site indicate a possible anatomical cause.
The clinical presentation of PIDs may include features of 
autoimmunity or inflammation, apart from those of infections. The 
JMF warning signs (Table 3) provide a useful guide to the need 
for investigation, but in the SA context have to include bacillus 
Calmette-Guérin (BCG) dissemination, recurrent meningococcal 
infections and awareness of infections with atypical mycobacteria. 
The following warning signs were found to be most predictive 
of PID in children: a family history of PID, use of intravenous 
antibiotics to treat sepsis and failure to thrive in T-lymphocyte 
PID.[8]
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The causative organisms may be defined as virulent, opportunistic, 
hospital or community acquired and assist in determining the relevant 
immunodeficiency to be investigated: deficiency for intracellular 
(e.g. TB) versus extracellular bacterial targeted immune responses. 
Infections with encapsulated organisms may point to a deficient 
immune response specific to Streptococcus pneumoniae, with antibody 
responses being crucial. T-cell PIDs, although commonly manifesting 
with intracellular infections, generally also involve B-cell-dependent 
(humoral) immune responses and hence result in bacterial infections. 
T-cell-related immune deficit manifests early in life, sometimes in the 
first months, whereas B-cell PIDs tend to present with symptoms at 
the time of loss of maternal passive antibodies in the infant, especially 
>6 months of age.
Basic laboratory screening (full blood count, differential count, 
immunoglobulins and complement) is readily available to identify 
the majority of significant defects. A more comprehensive four-step 
laboratory approach has been developed by the JMF and modified 
for use in SA.
Step 1. After exclusion of HIV and, where indicated on history, an 
assessment for atopy, the investigation starts with a full blood count 
and, importantly, differential count for neutrophil and lymphocyte 
numbers. A persistently low lymphocyte count for age, which should 
be >1/3 of leukocytes <3 years of age or >3.0 × 109/L, is an important 
indicator of possible severe combined immunodeficiency (SCID) 
or combined immunodeficiencies. A blood smear will assist, e.g. to 
identify small platelets as seen in Wiskott-Aldrich syndrome. Serum 
immunoglobulin (Ig) G, M, A and E, total complement activity and 
subsequent fractions as indicated by the absence of activity, cystic 
fibrosis screening and investigation for active TB where suspected on 
history and clinical examination complete step 1.
Step 2. Vaccine antibody response to a range of antigens but 
more targeted to polysaccharide-specific antigens (pneumococcus) 
and protein antigens (tetanus) is indicated with recurrent bacterial 
infections, even in the presence of normal immunoglobulin levels. 
Patients have to be off immunoglobulin replacement therapy for 6 
months. These responses should be repeated four weeks after vaccine 
boosting to determine an appropriate increase in IgG, of which there 
are four subclasses. These can be further investigated for deficiency of 
one or more, especially if total IgG levels are normal in the presence of 
Table 1. Spectrum of infections
Cellular/combined immunodeficiencies
Bacterial, e.g. Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus; viral, e.g. cytomegalovirus; fungal, e.g. Candida species, 
Histoplasmosis species; and protozoal, e.g. Pneumocystis jiroveci infections
Predominantly antibody deficiencies
Encapsulated bacteria, e.g. S. pneumoniae, H. influenzae, mycoplasma, chronic enterovirus infections
Defects of phagocyte number and/or function
Catalase-positive bacterial infections, e.g. S. aureus, Burkholderia cepacia, Serratia marcescens, Nocardia species, Escherichia coli, 
Pseudomonas aeruginosa, Mycobacterium tuberculosis (particularly in high-prevalence settings); non-tuberculous mycobacterial, 
bacillus Calmette-Guérin (BCG) and fungal infections, e.g. Aspergillus fumigatus
Defects in innate immunity
Produce an interesting spectrum of infections, e.g. IRAK-4/My88 deficiencies cause bacterial infections; human papillomavirus infection 
associated with warts, hypogammaglobulinaemia, infections, and myelokathexis (WHIM) syndrome and epidermodysplasia verruciformis (EVER) 
deficiencies; STAT2 deficiency causes disseminated vaccine-strain measles; TLR3, UNC93B1, TRAF3, TRIF and TBK1 deficiencies cause herpes 
encephalitis; and genetic defects in the interleukin-17 pathway may cause chronic mucocutaneous candidiasis
Early complement deficiencies
Encapsulated bacterial infections
Terminal C deficiencies (C5 - C9) and properdin deficiency
Recurrent neisserial infections 
Table 2. Major categories of primary immunodeficiency 
diseases (PIDs)
• Combined (T- and B-cell) immunodeficiencies
• Combined immunodeficiencies with associated or syndromic
features
• Predominantly antibody deficiencies
• Diseases of immune dysregulation
• Defects of phagocytic number, function or both
• Defects in innate immunity
• Autoinflammatory disorders
• Complement deficiencies
• Phenocopies of PIDs
Table 3. Ten warning signs of primary immunodeficiency 
developed by the Jeffrey Modell Foundation Medical Advisory 
Board[16]  
• Four or more new ear infections within one year
• Two or more serious sinus infections within one year
• Two or more months of antibiotics, with little effect
• Two or more pneumonias within one year
• Failure of an infant to gain weight or grow normally
• Recurrent, deep skin or organ abscesses
• Persistent thrush in mouth or fungal infection on skin
• Need for intravenous antibiotics to clear infections
• Two or more deep-seated infections including septicaemia
• A family history of primary immunodeficiency
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recurrent infections. Both IgG subclass deficiency and deficient vaccine 
antibody response, especially to S. pneumoniae, should be investigated 
concurrent with symptomatic IgA deficiency (IgA <0.08 g/L), as these 
are common associations.
Lymphocyte subsets are enumerated by flow cytometry with 
cluster of differentiation (CD) markers to document B-cell numbers 
(CD19), which are absent in X-linked agammaglobulinaemia when 
all immunoglobulin isotypes are severely reduced. Total T cells (CD3) 
are measured with the sum of T-helper (CD4) and T-suppressor 
(CD8) cells, and natural killer cells are measured as CD16 and CD56.
Step 3. Lymphocyte enumeration does not provide information on 
function, which can be done at specialised laboratories on request. 
The response to mitogens, e.g. phytohaemagglutinin, or to antigens, 
e.g. Candida, can give information on specific immune deficit or 
suppression. Neutrophil function, particularly in suspected deficiency 
such as CGD, can be evaluated with the neutrophil burst activity. 
This test, done on the mother in X-linked CGD, can also guide on 
possible carrier status. Neutrophil studies for leukocyte adhesion, 
chemotaxis and phagocytosis, lymphocyte subset definitions of naïve 
and memory status are all requested after specialist consultation.
Stage 4. Cytokine studies, enzyme studies and genetic molecular 
investigations are not generally available and can only be selectively 
done.
While neonatal screening for SCIDs is becoming routine practice 
in North America and Europe by T-cell-receptor excision circle assay, 
this is costly and only available on request in SA. Dissemination 
of routinely applied neonatal BCG vaccine remains an important 
alerting sign outside HIV infection.[9]
Management
Most interventions for managing PIDs are available to a varying 
degree in SA. 
Immunisation practice
Immunisation with live viral or bacterial vaccines poses an 
infection risk to individuals with severe PIDs of T-cell, B-cell and 
phagocytic origin, requiring modification to routine immunisation 
practice of children with PIDs and changes to the immunisation 
of household contacts of patients with PIDs. For example, recent 
evidence suggests that 51% of infants with SCID experience 
BCG-related complications following neonatal immunisation, 34% 
develop BCGosis and 17% develop localised BCG complications.[10] 
Oral polio and smallpox vaccines are contraindicated in children 
with severe antibody deficiencies. For children with combined 
B- and T-cell deficiencies, such as SCID, all live vaccines are 
contraindicated, and for those with phagocytic disorders live 
bacterial vaccines are contraindicated.[11]
Immunocompetent household contacts of PID patients should not 
receive smallpox or oral polio vaccine, because these vaccine virus 
strains may be transmitted to immunocompromised patients. Other 
vaccines may be administered to close contacts because they pose 
little risk of transmission to the PID patient.[11]
Antimicrobial prophylaxis
Several PIDs may benefit from antimicrobial prophylaxis. In 
milder antibody conditions, such as IgA deficiency or transient 
hypogammaglobulinaemia of infancy, recurrent infection may 
occasionally require short courses of prophylactic antibiotics. 
Antibiotic prophylaxis should be the first intervention for prevention 
in patients with specific antibody deficiency or IgG subclass deficiency 
and recurrent infection, before considering immunoglobulin 
replacement therapy (IRT). Antibiotic prophylaxis may be added in 
patients with severe antibody deficiency if IRT is unable to adequately 
prevent recurrent infections. Both antibacterial and antifungal 
prophylactic agents are required in children with severe phagocytic 
disorders. Prior to haematopoietic stem cell transplantation (HSCT), 
children with severe combined immunodeficiencies such as SCID 
require broad-spectrum antibacterial, antiviral and antifungal 
prophylaxis. Detailed prophylactic regimens have recently been 
published.[12] 
Immunoglobulin replacement therapy
Many predominantly antibody deficiencies and combined 
immunodeficiencies in which quantitative and/or qualitative IgG 
deficiency occurs may benefit from IRT. Lifelong IRT is required 
for severe, genetically confirmed deficiencies in which arrest 
in early B-cell development is demonstrated, such as X-linked 
agammaglobulinaemia. Incompletely defined predominantly 
antibody deficiencies characterised by the presence of circulating 
B cells and subnormal IgG concentration may require a 12-month 
trial of IRT, while documenting the clinical response. If the 
response is favourable, treatment may be extended for 1 - 5 years, 
followed by periodic re-evaluation of serum immunoglobulin 
concentrations as hypogammaglobulinaemia may be transient 
and resolve spontaneously. Functional antibody responses should 
ideally not be checked until IRT has been discontinued for at least 6 
months. If IgG deficiency persists, IRT should be restarted and may 
have to be continued indefinitely if the deficiency fails to resolve. 
Treatment with intravenous immunoglobulin is most widely used. 
Subcutaneous immunoglobulin administration is less frequently 
used but is equally effective. Intravenous immunoglobulin is 
administered at 3 - 4-week intervals at the usual starting dose 
of 400 mg/kg for patients without bronchiectasis and 600 mg/kg 
for those with bronchiectasis. After achieving steady state, an IgG 
trough concentration of >5  g/L reduces the infection rate and 
trough levels up to 10  g/L will progressively reduce the risk of 
pneumonia. Progressive adjustment of the total infusion dose is 
required to optimise the IgG trough concentration.[13]
Additional measures to control infection
General advice aimed at reducing the risk of infection will benefit 
many immunodeficient patients, including advice on personal, 
hand and dental hygiene, avoidance of exposure to individuals with 
active infections and annual influenza immunisation for household 
contacts. Antimicrobial prophylaxis is often administered with 
other interventions to reduce the risk of infection. In SCID, prior 
to an HSCT, the infant should ideally be managed in a laminar 
flow facility, with full contact precautions, and receive sterile 
feeds. In the immediate post-HSCT period, similar management 
interventions apply. In CGD, life-long interferon-γ is recommended 
in combination with co-trimoxazole and itraconazole prophylaxis. 
However, the high cost precludes its routine use in SA. In Job 
syndrome, which causes a markedly elevated IgE concentration, the 
risk of colonisation and infection with Staphylococcus aureus may be 
reduced by regular bleach or chlorhexidine soaks and intermittent 
mupirocin applications.
Haematopoietic stem cell transplantation 
This is the treatment of choice for many severe PIDs, including SCID. 
In SA, there is limited access to HSCT in the public sector. However, 
three children with SCID have been successfully transplanted, 
permitting the development of guidelines for the pre-HSCT 
management of children with SCID, including the tissue typing 
procedure and identification of suitable donors.[14]
CONTINUING MEDICAL EDUCATION
    November 2014, Vol. 104, No. 11
Other therapies
Other therapeutic modalities include cytokine therapy, such as 
myeloid haematopoietic growth factors for congenital and cyclical 
neutropenia, enzyme replacement for adenosine deaminase deficiency 
and C1-inhibitor deficiency, colchicine in familial Mediterranean 
fever (FMF), and interleukin 1-blocking agents in autoinflammatory 
disorders including patients with colchicine-resistant FMF. Gene therapy 
offers hope as a potential treatment and cure for PIDs in the future.[15]  
Conclusion 
PIDs worldwide are more common than is generally believed.[1] In 
SA, diagnosis may be masked by a high background prevalence of 
infectious diseases. It is hoped that this article  increases awareness of 
PIDs among general practitioners and paediatricians. 
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Useful information sources
• African Society for Immunodeficiency Diseases (ASID): http://www.asid.ma 
• Immune Deficiency Foundation (IDF): http://www.primaryimmune.org 
• International Patient Organization for Primary Immunodeficiency (IPOPI): http:// www.ipopi.org
• Primary Immunodeficiency Network South Africa (PiNSA): http://www.pinsa.org
• Primary Immunodeficiency Resource Center: http://www.info4pi.org
